Gilead Sciences Dirección

Dirección controles de criterios 3/4

El CEO de Gilead Sciences' es Dan O'Day , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es $22.61M, compuesta por 7.7% salario y 92.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.039% de las acciones de la empresa, por valor de €30.39M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 6.3 años, respectivamente.

Información clave

Dan O'Day

Chief Executive Officer (CEO)

US$22.6m

Compensación total

Porcentaje del salario del CEO	7.7%
Permanencia del CEO	5.2yrs
Participación del CEO	0.04%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	6.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Dan O'Day en comparación con los beneficios de Gilead Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$485m
Dec 31 2023	US$23m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$5b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$22m	US$2m	US$5b
Sep 30 2022	n/a	n/a	US$3b
Jun 30 2022	n/a	n/a	US$4b
Mar 31 2022	n/a	n/a	US$5b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$7b
Jun 30 2021	n/a	n/a	US$5b
Mar 31 2021	n/a	n/a	US$301m
Dec 31 2020	US$19m	US$2m	US$123m
Sep 30 2020	n/a	n/a	US$1b
Jun 30 2020	n/a	n/a	-US$257m
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$29m	US$1m	US$5b

Compensación vs. Mercado: La compensación total de Dan($USD22.61M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD5.59M).

Compensación vs. Ingresos: La compensación de Dan ha sido consistente con los resultados de la empresa en el último año.

CEO

Dan O'Day (59 yo)

5.2yrs

Permanencia

US$22,607,690

Compensación

Mr. Daniel P. O'Day, also known as Dan, served as Non-Executive Non-Independent Director for Galapagos NV since October 22, 2019 until March 26, 2024. He served as Member of Supervisory Board at Galapagos...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel P. O'Day	Chairman & CEO	5.2yrs	US$22.61m	0.039% $ 29.6m
Andrew Dickinson	Chief Financial Officer	4.5yrs	US$8.11m	0.011% $ 8.2m
Deborah Telman	Executive VP of Corporate Affairs	1.8yrs	US$5.27m	0.0011% $ 860.5k
Johanna Mercier	Chief Commercial Officer	4.8yrs	US$8.59m	0.0095% $ 7.2m
Merdad Parsey	Chief Medical Officer	4.5yrs	US$8.39m	0.0077% $ 5.9m
Sandra Patterson	Senior VP	1.2yrs	sin datos	0.0026% $ 2.0m
Jacquie Ross	Vice President of Investor Relations	3.3yrs	sin datos	sin datos
Jyoti Mehra	Executive Vice President of Human Resources	4.8yrs	sin datos	sin datos
Linda Higgins	Senior Vice President of Research	4.3yrs	sin datos	sin datos
Rudolf Ertl	Senior Vice President of Commercial Operations of Australia	no data	sin datos	sin datos
Flavius Martin	Executive Vice President of Research	3.1yrs	sin datos	sin datos
William Grossman	Senior Vice President & Therapeutic Area Head of Gilead Oncology	2.8yrs	sin datos	sin datos

4.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GIS se considera experimentado (4.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Daniel P. O'Day	Chairman & CEO	5.2yrs	US$22.61m	0.039% $ 29.6m
Anthony Welters	Independent Director	3.6yrs	US$444.92k	0.00064% $ 487.4k
Paul Berg	Member of Scientific Advisory Board	no data	US$16.00k	sin datos
Jacqueline Barton	Independent Director	6.3yrs	US$429.92k	0.0018% $ 1.4m
Eugene Schiff	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Robert Schooley	Member of the Scientific Advisory Board	no data	sin datos	sin datos
John Mellors	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Francis Chisari	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Paul Klotman	Member of the Scientific Advisory Board	no data	sin datos	sin datos
Kevin Lofton	Lead Independent Director	14.8yrs	US$507.44k	0.0074% $ 5.7m
Kelly Kramer	Independent Director	7.8yrs	US$434.92k	0.00011% $ 83.8k
Joel Huff	Chairperson of Scientific Advisory Board	no data	sin datos	sin datos

6.3yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de GIS se considera experimentada (6.3 años de antigüedad promedio).

Gilead Sciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Insufficient new directors

Recent updates

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

First quarter 2024 earnings released: US$3.34 loss per share (vs US$0.81 profit in 1Q 2023)

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Fourth quarter dividend of US$0.77 announced

New minor risk - Financial position

Full year 2023 earnings released: EPS: US$4.54 (vs US$3.66 in FY 2022)

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Upcoming dividend of US$0.75 per share at 3.8% yield

New minor risk - Financial position

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.75 (vs US$1.43 in 3Q 2022)

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gilead Sciences, Inc. to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting®? 2023

Insufficient new directors

Gilead Sciences, Inc. Presents New Data Supporting Sunlenca®? (Lenacapavir) as an Important Treatment Option for Adults with Multi-Drug Resistant HIV

Gilead Sciences, Inc. Announces New Long-Term Real-World Data from BICSTaR Study Highlighting Safety and Efficacy Profile of Biktarvy as Treatment Regimen for Broad Range of People with HIV, Including Those with Prior Treatment History or Comorbidities

Gilead Sciences, Inc. Announces New Clinical Trial in Europe to Assess Lenacapavir for HIV Prevention as Part of Purpose Program

Gilead Demonstrates the Impact of Global Collaboration in Advancing Hiv Research and Health Equity At EACS 2023

Gilead Sciences, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Gilead Sciences, Inc. Announces CHMP of EMA Adopts Positive Opinion to Extend Use of Veklury (Remdesivir) to Treat COVID-19 in People with Hepatic Impairment

Kite, A Gilead Company Announces Car T-Cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients with Relapsed/Refractory Large B-Cell Lymphoma

Gilead Sciences, Inc.'s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer

Upcoming dividend of US$0.75 per share at 4.0% yield

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approval of Supplemental New Drug Application (sNDA) for the Use of Veklury (remdesivir)

New minor risk - Financial position

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.84 (vs US$0.91 in 2Q 2022)

European Commission Approves Gilead’S Trodelvy for Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial

Gilead Sciences, Inc. Presents New Biktarvy® Data at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic

Gilead Sciences, Inc. to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS

Gilead Sciences, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer

Gilead Sciences, Inc. Announces Week 96 Results from the Pivotal MYR301 Phase 3 Clinical Trial Evaluating the First-In-Class Entry Inhibitor Hepatitis Delta

Upcoming dividend of US$0.75 per share at 3.9% yield

Gilead Sciences, Inc. Announces Longer-Term Overall Survival Results from the Phase 3 Tropics-02 Study Evaluating Trodelvy® Versus Comparator Chemotherapy

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad